Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
NCT ID: NCT02533609
Last Updated: 2020-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
30 participants
OBSERVATIONAL
2015-09-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. whether and to what extent antibiotic drugs (piperacillin/tazobactam and imipenem/cilastatin) are removed during citrate-anticoagulated CVVHD per se
2. whether filter patency during citrate-anticoagulated CVVD remains stable during a treatment period of 72 h
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy
NCT02611271
Investigating Different Anticoagulants for Renal Replacement Therapy
NCT02669589
Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement Therapy
NCT01269112
Nephroprotective Measures in Critically Ill Patients With Moderate/Severe Acute Kidney Injury
NCT06472999
Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis
NCT06253377
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Piperacillin/Tazobactam
Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
No interventions assigned to this group
Imipenem/Cilastatin
Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 y
Exclusion Criteria
* Pregnancy
* Contraindications against citrate-anticoagulation or continous renal replacement therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fresenius Medical Care Deutschland GmbH
INDUSTRY
Heinrich-Heine University, Duesseldorf
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Klinik für Anästhesiologie
Prof. Dr. D. Kindgen-Milles
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Detlef Kindgen-Milles, Prof.
Role: STUDY_DIRECTOR
Department of Anesthesiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prof. Kindgen-Milles
Düsseldorf, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-02-ENDVERSION
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.